Literature DB >> 60452

Suppression of reaging antibody formation. IV. Suppression of reaginic antibodies to penicillin in the mouse.

W Y Lee, A H Sehon.   

Abstract

Reaginic antibodies to the benzylpenicilloyl determinant (BPO) and ovalbumin (OA) were induced readily in B6D2F1 mice by a single i.p. injection of either 1 or 10 mug of BPO4-OA suspended with 1 mg of Al(OH)3 in 0.5 ml of saline. Administration of conjugates consisting of the hapten coupled to the isologous, nonimmunogenic murine gamma-globulins (MgammaG), i.e., BPO9-MgammaG, BPO11-MgammaG, or BPO12-MgammaG, resulted in complete and specific suppression of the induction of the anti-BPO reaginic antibody response without affecting, however, the level of reaginic antibodies to OA. Further study of the effect of epitope density on the immunologic properties of BPOX-MgammaG revealed that a) the lightly haptenated conjugated, BPO1-MgammaG and BPO2.9-MgammaG, were not immunosuppressive, b) the conjugates, BPO4.3-MgammaG and BPO19-MgammaG, were partially tolerogenic, and c) the heavily haptenated conjugate, BPO31-MgammaG, was nontolerogenic. Moreover, most importantly, the ongoing anti-BPO response in sensitized mice was readily abrogated by either four daily or four weekly injections of BPO9-MgammaG. The immunosuppressive effect of BPO12-MgammaG conjugates was dose dependent, complete suppression being achieved with 200 mug of the tolerogen. The unresponsiveness to BPO of spleen cells from immunosuppressed donors was also maintained in adoptive cell transfer experiments in spite of the additional administration of the immunizing antigen under conditions expected to yield a secondary IgE response. Hence, it is suggested that, with special precautions to prevent unleashing an anaphylactic shock, treatment of penicillin-sensitive individuals with polyvalent conjugates of an appropriate number of BPO groups per human gamma-globulin molecule would constitute a rational immunotherapeutic procedure for the abrogation of the allergic response to BPO.

Entities:  

Mesh:

Substances:

Year:  1976        PMID: 60452      PMCID: PMC8335344     

Source DB:  PubMed          Journal:  J Immunol        ISSN: 0022-1767            Impact factor:   5.422


  9 in total

1.  Profound specific suppression by antigen of persistent IgM, IgG, and IgE antibody production.

Authors:  H M Dintzis; R Z Dintzis
Journal:  Proc Natl Acad Sci U S A       Date:  1992-02-01       Impact factor: 11.205

2.  Allergic bronchial asthma due to Dermatophagoides pteronyssinus hypersensitivity can be efficiently treated by inoculation of allergen-antibody complexes.

Authors:  J J Machiels; M A Somville; P M Lebrun; S J Lebecque; M G Jacquemin; J M Saint-Remy
Journal:  J Clin Invest       Date:  1990-04       Impact factor: 14.808

Review 3.  Penicillin allergy.

Authors:  J E Erffmeyer
Journal:  Clin Rev Allergy       Date:  1986-05

Review 4.  Novel approaches in immunotherapy.

Authors:  J M Saint-Remy
Journal:  Clin Rev Allergy       Date:  1994

5.  Generation of immunological memory in tolerant mice.

Authors:  J P Tite; J H Playfair
Journal:  Immunology       Date:  1978-06       Impact factor: 7.397

6.  Specific immunosuppression of IgE response to hapten DNP by linked to monoclonal IgG1 in rats.

Authors:  D Pan; W Y Lee; M S Shiao
Journal:  Experientia       Date:  1982-04-15

7.  Hapten-specific T-cell unresponsiveness induced bybenzylpenicilloyl autologous gamma globulin conjugates in human lymphocyes in vitro.

Authors:  R S Geha; L Fruchter; Y Borel
Journal:  J Clin Invest       Date:  1980-06       Impact factor: 14.808

8.  Studies of migration inhibition tests in penicillin hypersensitivity.

Authors:  R J Warrington; P J Sauder; W J Rutherford
Journal:  Clin Exp Immunol       Date:  1979-10       Impact factor: 4.330

9.  The use of hapten-polysaccharide conjugates for the induction of B-cell tolerance involving IgE responses. I. Preparation, characterization and specific tolerogenic activity of penicilloy l-substituted levans affecting IgE responses in normal and sensitized mice.

Authors:  C Moreno; C Hale; R Hewett
Journal:  Clin Exp Immunol       Date:  1978-03       Impact factor: 4.330

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.